Molnupiravir 200 mg

Description

What is Molnupiravir?

It belongs to the class of antivirals called mutagenic ribonucleosides. Mutagenic ribonucleosides are broad-spectrum antiviral agents that prevent mutation of RNA virus from preventing it from replicating further. Molnupiravir Uk is a prodrug of the synthetic nucleoside derivative N4-hydroxycitidine and is currently in the news for its use in SARS-CoV-2 virus cases.

What is Molnupiravir UK used for?

It was developed to treat influenza by DRIVE, but its development halted midway for its mutagenic activities. This mutagenic property enabled researchers to declare its effectiveness against the SARS-COVID virus through multiple randomized, double-controlled trials. It is the only FDA-approved antiviral drug for emergency use in Covid positive patients. Read here to know more about it.

What are the ingredients of Molnupiravir?

It comes in hard capsule form with engravings on its surface. The capsule contains Croscarmellose sodium, hydroxypropyl cellulose, magnesium stearate, and microcrystalline cellulose. The capsule shell contains Hypromellose, titanium dioxide, and red iron oxide. The printing ink contains butyl alcohol, dehydrated alcohol, purified water, and shellac.

What is Molnupiravir mechanism of action?

Animal models have proved the drug works by increasing the frequency of viral RNA mutations and thus impairing the Sars-Covid virus from replicating further. This enables the further spread of the virus and provides the immune system the required time to start its protective action. The prodrug property of the medication is said to play a role in its effectiveness.

What is Molnupiravir FDA status, and when will it be available?

In the earlier days, the FDA had not approved the medicine for any use due to confusion regarding its unresearched mutagenic property. In lieu of the growing cases of the Sars-Covid virus, the US Food and Drug Administration on December 2021 issued an emergency use authorization for Covid positive patients at high risk of progressive symptoms.

What are Molnupiravir Covid statistics in the UK?

In a study conducted on 202 Covid positive patients, participants were randomized to either a 1:1 ratio of Molnupiravir 200mg and placebo or a 3:1 ratio of the antiviral medicine (400 or 800mg) or placebo twice daily for 5 days. It was noticed that viral isolation was significantly lower in patients receiving 800mg Molnupiravir versus placebo with additional good tolerance of the drug.

How does Molnupiravir cause viral isolation?

It is a prodrug that metabolizes into a ribonucleoside analog resembling cytidine phosphate or NHC-TP, which is replicated by the viral enzyme. It can swap between two forms and mimic cytidine and uridine. On trying to copy RNA containing Molnupiravir, it misinterprets the type leading to mutation errors and subsequently the death of it.

What is the dosage of Molnupiravir in the UK?

It is available in a strength of 200 mg in capsule form. An 800mg dosage is given for 5 days with a gap of 12 hours in Covid positive patients showing mild to moderate symptoms. It is not authorized for patients hospitalized due to Covid complications or as a prophylactic measure. It is also not authorized for use for more than 5 days after starting the drug.

How long does Molnupiravir take to start working on the human body?

It has a peak plasma time of 1.5 hours with a peak plasma concentration of 2330ng/ml in patients with 2970ng/ml in healthy subjects. It is taken on an empty stomach as its ingestion with food leads to a 35% reduction in peak plasma concentration. Post its clearance of 76.9L/ hour, it is metabolized and excreted by the liver and kidney, respectively. It has a half-life of 3.3 hours.

Where to buy Molnupiravir in UK?

Molnupiravir UK is a prescription medication. You need a prescription to avail of it from registered pharmacies or in any physician’s clinic. You can also order Molnupiravir online. It is the best way to quickly, efficiently and cost-effectively access medicine. But it is important to buy the medicine from an authentic site so you can avail a genuine product. Post-delivery check for the package for tampering signs, if any.

Can Molnupiravir be used in pregnant and breastfeeding ladies?

It should not be used in pregnant and breastfeeding ladies as it may cross the blood-brain barrier and lead to fetal harm in the brain development of infants. Breastfeeding is not recommended during treatment with the anti-viral medication and for four days after the final dose. Additionally, people of reproductive potential should use contraceptives during their use.

What are the side effects of Molnupiravir?

Nausea, dizziness, headache, and diarrhea are some of the common side effects. But based on the final analysis of the drug, no major adverse reactions have been found on using the medication. Nonetheless, if you experience any severe side effects, you must seek medical help. It is not recommended for children and adults below 18 years of age, affecting bone and cartilage growth.

Are there any drug interactions with Molnupiravir?

The drug interactions of this anti-viral medicine have not been identified as of now because of its limited use and recent entry into the medical field. It is advised to take it on an empty stomach as food tends to reduce its peak concentration rate. Additionally, the use of Molnupiravir is contraindicated with that of alcohol, especially while driving or operating heavy machinery.

What if I miss a dose of Molnupiravir?

If you’ve missed the dose 10 hours prior, take one tablet as soon as possible and resume dosing as per the normal schedule. If more than 10 hours have passed, skip the dose and take it at the next scheduled time period. Do not overdose or double dose the medication to make up for the missed dose.

What is the latest news regarding Molnupiravir?

Based on its effectiveness in randomized clinical trials, It has been approved for medical use in the United Kingdom in November 2021. Along with the FDA of the United States granting emergency approval for the drug, the SEC has granted permission to manufacture and market Molnupiravir as per the required strengths and doses.